Human coronary atherosclerosis modulates cardiac natriuretic peptide release

被引:28
作者
Barbato, Emanuele [1 ]
Rubattu, Speranza [2 ,3 ]
Bartunek, Jozef [1 ]
Berni, Andrea [2 ]
Sarno, Giovanna [1 ]
Vanderheyden, Marc [1 ]
Delrue, Leen [1 ]
Zardi, Domenico [2 ]
Pace, Biagio [2 ]
De Bruyne, Bernard [1 ]
Wijns, William [1 ]
Volpe, Massimo [2 ,3 ]
机构
[1] Cardiovasc Ctr OLV Aalst, Aalst, Belgium
[2] Univ Roma La Sapienza, S Andrea Hosp, Dept Cardiol, Rome, Italy
[3] IRCSS Neuromed, Pozzilli, Italy
关键词
Angina; Atherosclerosis; Endothelium; Natriuretic peptides; Vasoconstriction; FRACTIONAL FLOW RESERVE; SMOOTH-MUSCLE CELLS; C-TYPE; HEART-DISEASE; ESSENTIAL-HYPERTENSION; CARDIOVASCULAR EVENTS; ENDOTHELIAL-CELLS; CONSCIOUS SHEEP; MOLECULAR-FORMS; CYCLIC-GMP;
D O I
10.1016/j.atherosclerosis.2009.01.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natriuretic peptides (NPs) modulate vasodilatation and vascular remodelling. In human coronary explants, expression of NPs mRNA and their respective receptors is significantly more pronounced with advanced atherosclerotic lesions. Aims: We hypothesize that vascular atherosclerosis modulates NP release in vivo during progressive stages of coronary atherosclerosis. Methods and results: NT-proANP (A) and NT-proBNP (B) were assessed on blood samples of 194 patients. Coronary atherosclerosis was assessed in all patients by angiography and in case of moderate stenosis by fractional flow reserve (FFR), a validated tool for detecting ischemia-inducing stenosis. Significant coronary stenosis was defined as a diameter stenosis (DS) >= 50% and/or positive FFR. Endothelial dysfunction was detected by cold pressure test (CPT) in a subgroup of 99 patients. Patients were divided into: (1) normal group (normal endothelial function, n = 19); (2) endothelial dysfunction group (n = 17); (3) moderate atherosclerotic group (at least one coronary stenosis <50%, n = 86); (4) stenotic group (n = 72). A and B were higher in patients with endothelial dysfunction (A: 2951 [1290-3920] fmol/ml; 13: 156 [98-170] pg/ml), moderate atherosclerotic (A: 3868 [2250-5890] fmol/ml, p < 0.05 vs. normal: B: 162 [84-283] pg/ml) and stenotic group (A: 3934 [2647-5525]; B: 227 [191-784] pg/ml; p < 0.05 vs. normal) as compared with normal group (A: 2378 [970-2601] fmol/ml; B: 78 [40-136] pg/ml). During CPT, a mild NT-proANP increase was observed only in patients with endothelial dysfunction (Delta% vs. baseline: 17 +/- 6, p < 0.05). NT-proBNP did not change after CPT in all groups. Conclusion:Well defined stages of atherosclerosis are characterized by progressive increases in NT-proANP and NT-proBNP levels, beginning with endothelial dysfunction and progressively more pronounced with moderate and severe coronary atherosclerosis irrespective of the underlying myocardial disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:258 / 264
页数:7
相关论文
共 48 条
  • [1] MOLECULAR-FORMS OF ATRIAL NATRIURETIC PEPTIDE IN THE ATRIUM OF PATIENTS WITH CARDIOVASCULAR-DISEASE
    AKIMOTO, K
    MIYATA, A
    KANGAWA, K
    KOGA, Y
    HAYAKAWA, K
    MATSUO, H
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (01) : 93 - 97
  • [2] Altman DG, 1991, PRACTICAL STAT MED R, Vxii
  • [3] Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure
    Arad, M
    Elazar, E
    Shotan, A
    Klein, R
    Rabinowitz, B
    [J]. CARDIOLOGY, 1996, 87 (01) : 12 - 17
  • [4] Role of β2 adrenergic receptors in human atherosclerotic coronary arteries
    Barbato, E
    Piscione, F
    Bartunek, J
    Galasso, G
    Cirillo, P
    De Luca, G
    Iaccarino, G
    De Bruyne, B
    Chiariello, M
    Wijns, W
    [J]. CIRCULATION, 2005, 111 (03) : 288 - 294
  • [5] Alpha-adrenergic receptor blockade and hyperaemic response in patients with intermediate coronary stenoses
    Barbato, E
    Bartunek, J
    Aarnoudse, W
    Vanderheyden, M
    Staelens, F
    Wijns, W
    Heyndrickx, GR
    Pijls, NHJ
    De Bruyne, B
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (22) : 2034 - 2039
  • [6] Validation of coronary flow reserve measurements by thermodilution in clinical practice
    Barbato, E
    Aarnoudse, W
    Aengevaeren, WR
    Werner, G
    Klauss, V
    Bojara, W
    Herzfeld, I
    Oldroyd, KG
    Pijls, NHJ
    De Bruyne, B
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (03) : 219 - 223
  • [7] Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans
    Barletta, G
    Lazzeri, C
    Vecchiarino, S
    Del Bene, R
    Messeri, G
    Dello Sbarba, A
    Mannelli, M
    La Villa, G
    [J]. HYPERTENSION, 1998, 31 (03) : 802 - 808
  • [8] B-type natriuretic peptide and ischemia in patients with stable coronary disease - Data from the Heart and Soul Study
    Bibbins-Domingo, K
    Ansari, M
    Schiller, NB
    Massie, B
    Whooley, MA
    [J]. CIRCULATION, 2003, 108 (24) : 2987 - 2992
  • [9] Natriuretic peptide system gene expression in human coronary arteries
    Casco, VH
    Veinot, JP
    de Bold, MLK
    Masters, RG
    Stevenson, MM
    de Bold, AJ
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2002, 50 (06) : 799 - 809
  • [10] Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep
    Charles, CJ
    Espiner, EA
    Richards, AM
    Nicholls, MG
    Yandle, TG
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1996, 270 (06) : R1324 - R1331